Clinical Trials
6 trialsNCT07131254 2025-12-30
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors
Grit Biotechnology
Phase EARLY_PHASE1 Recruiting
NCT03537482 2024-08-19
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
Ascentage Pharma Group Inc.
Phase EARLY_PHASE1 Recruiting
NCT05707325 2024-07-24
Reboot-101
Westlake Therapeutics
Phase EARLY_PHASE1 Recruiting
NCT03795779 2021-05-19
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown
NCT04700319 2021-03-08
CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04156256 2019-11-12
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown